Seven non-diabetic patients with chronic pancreatitis were shown to have a diminished acute insulin secretory response after intensive beta cell and intravenous tolbutamide stimulation. In an attempt to unmask their 'latent' diabetic state, triamcinolone-augmented glucose tolerance tests were performed some days after documenting normal standard 50 g oral glucose tolerance tests. A matched group of non-diabetic controls was similarly investigated. Although the steroid-augmented glucose tolerance tests showed marked impairment in the patients, becoming frankly diabetic in three cases, the normal control subjects reacted in a similar though less striking fashion. There was no significant difference between the mean glucose values in the two groups. The ability of patients with chronic pancreatitis to maintain normal glucose tolerance in the face of diminished insulin output is commented on. We conclude that, as an ancillary investigation for diagnosing chronic pancreatitis, the triamcinolone glucose tolerance test is unreliable.
Introduction
Although chronic pancreatitis is frequently complicated by diabetes, there are, nevertheless, a substantial number of patients who maintain normal glucose tolerance Anderson et al., 1970) . Recent studies Deckert et al., 1972) have indicated that even when glucose tolerance is apparently unaffected in chronic pancreatitis, insulin reserve has already been significantly decreased. Thus non-diabetic patients with chronic pancreatitis could be regarded as 'prediabetic' subjects (Rogers, Howard and Pairent, 1970 (Bank et al., 1963 
Experimental design
The insulin secretory capacity of the patients and controls was first established using the techniques of: (a) intensive beta cell stimulation with a combination of 75 g oral glucose, followed 30 min later by the combined intravenous administration of 2 g tolbutamide and 1 mg glucagon (Ryan, Nibbe and Schwartz, 1967) ; and (b) intravenous administration of 1 g tolbutamide alone (undertaken some days later). In each test, serum samples for immunoreactive insulin determinations were obtained fasting and after stimulation. Since the 5 min post-injection sample in each test generally represented the peak insulin response, this (together with the fasting sample) was used for subsequent analysis. Oral GTTs were then performed, at a later date, in both groups of subjects. For the standard GTT, 50 g of glucose was administered orally after an overnight fast and employing the usual precautions (Jackson, 1964) . Triamcinolone-augmented GTTs were done at least 2 days later, using triamcinolone 8 mg 11 hr and 1 hr before the 50 g oral glucose load.
Methods
Glucose was determined half hourly for 2 hr on capillary whole blood using a Technicon AutoAnalyzer and the modified ferricyanide method of Hoffman (1937) . In addition, hourly urine samples were tested for glycosuria with Testape. Serum insulin during the intensitive beta cell stimulation and tolbutamide tests were measured by radioimmunoassay (Hales and Randle, 1963) .
Criteria for analysis of GTTs
For both the standard GTT and the triamcinolone GTT the same criteria were used (Jackson et al., 1972) . Normal: all blood glucose levels below 120 mg/100 ml fasting, 185 maximum and 140 at 120 min. Borderline: one high value only. Diabetic: at least 2 high values.
Results Table 1 indicates the acute insulin secretory capacity of the non-diabetic patients with chronic pancreatitis, together with that of the matched controls, as evidenced by their fasting and early insulin responses to intensive stimulation and tolbutamide alone. Fasting insulin levels were similar in the two groups, but the patients produced less than half the peak insulin output of the controls after intensive stimulation. A similar, although statistically less impressive, response was noted after tolbutamide alone. (Mean 30 min %o blood glucose falls after tolbutamide were similar in the two groups, at 35%/ in patients and 43°/ in controls).
The results of the standard and triamcinoloneaugmented GTTs in the two groups are outlined in Table 2 . Standard GTTs were normal in both groups, as anticipated; none of the differences between the mean values were statistically significant. Regarding triamcinolone GTTs, a statistically significant deterioration (compared to standard GTT) occurred in both groups (P < 0 05 at 60, 90 and 120 min). Although the mean glucose level was generally higher in the pancreatitis patients than in the controls during the triamcinolone test, at no time did it become significantly greater. Of interest was the observation that the mean triamcinolone GTT had, in fact, become 'diabetic' in the chronic pancreatitis patients, while still remaining 'normal' in the controls.
Glycosuria was uniformly absent during standard GTTs. It was detected in all seven chronic pancreatitis patients during the triamcinolone GTT, but also in four of the seven controls. Table 3 summarizes the fate of individual triamcinolone GTTs in the two groups, analysed according to the criteria set out earlier. The test became diabetic in three patients and one control.
Discussion
The primary object of the present study was to ascertain wheher a steroid-augmented glucose tolerance test would be a useful ancillary investigation in chronic pancreatitis, by unmasking the diabetes susceptibility of those patients who preserve normal glucose tolerance in the face of diminished insulin reserve. Although marked deterioration in the triamcinolone GTT was, indeed, noted and nearly half the tests became diabetic, much of the impact of these observations was lost in view of the fact that normal controls reacted in a similar, though less striking, manner. This lack of specificity of the triamcinolone GTT has recently been commented on in relation to offspring of diabetic couples (Jackson et al., 1972) . It would thus appear that an abnormal triamcinolone GTT in a non-diabetic patient with suspected chronic pancreatitis is of uncertain diagnostic reliability. The pathogenesis of steroid 'diabetes' is not very clear, but direct antagonism of insulin at a cellular level seems to be an important factor (Berger et al., 1966) . This results in compensatory hypersecretion of insulin, both from the acutely releasable and slowly responding functional insulin pools in the beta cell (Porte and Bagdade, 1970) , and if this is inadequate, impaired carbohydrate tolerance will ensue. In chronic pancreatitis, the defect in insulin output appears to mainly involve its early secretion from the acutely releasable insulin pool (Porte and Bagdade, 1970) , so that a steroid-augmented GTT may not be the most effective means of revealing this abnormality. Agents that more directly compromise the early release of insulin from the beta cell, such as epinephrine, diazoxide and mannoheptulose (Levine, 1970) might have greater diagnostic merit in this regard.
Finally, the ability of patients with chronic pancreatitis to maintain normal glucose tolerance in the face of considerably diminished insulin secretory capacity is of interest. It implies a state of insulin sensitivity in chronic pancreatitis, and this has indeed been demonstrated after exogenous insulin administration (Joffe, Bank and Marks, 1968) . Reasons for this are speculative, although decreased secretion of anti-insulin factors, such as growth hormone (Vinik et al., 1970) , and pancreatic glucagon (Persson et al., 1971 ) may be partly responsible.
